Fosun Pharma’s Global R&D Head On Original Innovation In China

Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.

Xingli Wang
Xingli Wang, CEO of the Global R&D Center of Shanghai Fosun Pharmaceutical (Group) (Fosun Pharma)

More from Interviews

More from Scrip